alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>   1
                                                                    EXHIBIT 4.2

                      [STANDARD CHARTERED BANK LETTERHEAD]


DATE: 2nd March 2001

OUR REF: C&/LC/TEAM3/BKE


CONFIDENTIAL

Jetcrown Industrial Ltd.
Units 516-517,
Hong Leong Industrial Complex,
No. 4 Wang Kwong Road,
Kowloon Bay,
Kowloon.

Attn.: Ms. Eliza Y.P. Pang



Dear Sirs,

                  BANKING FACILITIES: JETCROWN INDUSTRIAL LTD.


We refer to our letter dated 9th March 2000 setting out the facilities made
available to your company (the "Company").

Following our recent discussions, we are pleased to confirm that the facilities
have been renewed on an unchanged basis except the following variations:


INTEREST, COMMISSIONS AND FEES

The second paragraph under this heading is revised to read as follows:

Letters of Credit Opening Commission & Commission in lieu of Exchange


<TABLE>
<S>                                              <C>
up to USD100,000.-                                1/8%
(previously first USD50,000.-                     1/4%)
(USD50,001 TO USD100,000.-                        1/8%)
Balance                                           1/32% (unchanged)
</TABLE>


An arrangement fee of HKD5,000.- will be debited to your current account. The
arrangement fee is nonrefundable in any event.

This letter will amend the terms of the existing facility letter which the Bank
has issued to the Company, as set out above. In all other respects, the terms of
the existing facility letter will remain in full force and effect. This letter
will be governed by Hong Kong SAR law.
<PAGE>   2
                                                       [STANDARD CHARTERED LOGO]



JETCROWN INDUSTRIAL LTD.                                                  PAGE 2



If you have any queries, please contact your Senior Relationship Manager Ms.
Angela Leung, whose telephone number is 2282-6415. ,

We are pleased to be of service to you and take this opportunity to thank you
again for your custom.

Yours faithfully,
For and on behalf of STANDARD CHARTERED BANK


/s/ JOSEPHINE TO
--------------------------------------------
Josephine To
Credit Documentation Manager
JT/kc
§ 139.122 Enriched nonfat milk macaroni products. ( a ) Each of the enriched macaroni products made with nonfat milk for which a definition and standard of identity is prescribed by this section conforms to the definition and standard of identity, and is subject to the requirements for label statement of ingredients, prescribed for macaroni products by § 139.110(a), (f)(2), (f)(3), (f)(4), and (g), except that: ( 1 ) ( i ) In preparing the dough, nonfat dry milk or concentrated skim milk, or a mixture of these, is used in an amount such that the finished enriched macaroni product made with nonfat milk contains by weight not less than 12 percent and not more than 25 percent of milk solids-not-fat. Carrageenan or the salts of carrageenan conforming to the requirements of § 172.620 and § 172.626 of this chapter may be used in a quantity not in excess of 0.833 percent by weight of the milk solids-not-fat used.
( ii ) When the ingredient carrageenan or the salts of carrageenan specified in paragraph (a)(1)(i) of this section is used, the label shall bear the statement, “Carrageenan added” or “Salts of carrageenan added” or the statement “With added carrageenan” or “With added salts of carrageenan”, in the manner further prescribed by § 139.110(f)(4).
( 2 ) None of the optional ingredients permitted by § 139.110(a) (1), (2), and (5) are used.
( 3 ) Each such food contains in each pound not less than 4.0 milligrams (mg) and not more than 5.0 mg of thiamin, not less than 1.7 mg and not more than 2.2 mg of riboflavin, not less than 27 mg and not more than 34 mg of niacin or niacinamide, not less than 0.9 mg and not more than 1.2 mg of folic acid, and not less than 13 mg and not more than 16.5 mg of iron (Fe). These substances may be added through direct addition or wholly or in part through the use of dried yeast, dried torula yeast, partly defatted wheat germ (as provided for in paragraph (a)(4) of this section), enriched farina, or enriched flour. They may be added in a harmless carrier, such carrier being used only in the quantity reasonably necessary to effect an intimate and uniform distribution of such substances in the finished food. Iron may be added only in a form that is harmless and assimilable.
( 4 ) Each such food may also contain as an optional ingredient partly defatted wheat germ, but the amount thereof does not exceed 5 percent by weight of the finished food.
( b ) The name of each food for which a definition and standard of identity is prescribed by this section is “Enriched macaroni product made with nonfat milk” or, alternatively, the name is “Enriched macaroni made with nonfat milk”, “Enriched spaghetti made with nonfat milk”, or “Enriched vermicelli made with nonfat milk,” as the case may be when the units of the food conform to the specifications of shape and size prescribed by § 139.110 (b), (c), or (d), respectively.
[42 FR 14409, Mar. 15, 1977, as amended at 58 FR 2878, Jan. 6, 1993]
#### § 814.40 Time frames for reviewing a PMA.

Within 180 days after receipt of an application that is accepted for filing and to which the applicant does not submit a major amendment, FDA will review the PMA and, after receiving the report and recommendation of the appropriate FDA advisory committee, send the applicant an approval order under § 814.44(d), an approvable letter under § 814.44(e), a not approvable letter under § 814.44(f), or an order denying approval under § 814.45. The approvable letter and the not approvable letter will provide an opportunity for the applicant to amend or withdraw the application, or to consider the letter to be a denial of approval of the PMA under § 814.45 and to request administrative review under section 515 (d)(4) and (g) of the act.

[51 FR 26364, July 22, 1986, as amended at 87 FR 2045, Jan. 13, 2022]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7606 Engrossed in House (EH)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
118th CONGRESS
  2d Session
                                H. R. 7606

_______________________________________________________________________

                                 AN ACT

 
 To designate the facility of the United States Postal Service located 
 at 1087 Route 47 South in Rio Grande, New Jersey, as the ``Carlton H. 
                      Hand Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CARLTON H. HAND POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 1087 Route 47 South in Rio Grande, New Jersey, shall be 
known and designated as the ``Carlton H. Hand Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Carlton H. 
Hand Post Office Building''.

            Passed the House of Representatives June 3, 2024.

            Attest:

                                                                 Clerk.
118th CONGRESS

  2d Session

                               H. R. 7606

_______________________________________________________________________

                                 AN ACT

 To designate the facility of the United States Postal Service located 
 at 1087 Route 47 South in Rio Grande, New Jersey, as the ``Carlton H. 
                      Hand Post Office Building''.
```
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM PAN
INTERNATIONAL GAMING, INC. AND SUBSIDIARY-INTERIM CONSOLIDATED FINANCIAL
STATEMENTS FOR THE PERIOD ENDING SEPTEMBER 30, 1999 AND FOR THE YEARS ENDING
DECEMBER 31, 1998 AND DECEMBER 31, 1997 FORM 10QSB FOR 3RD QUARTER, 1999 ENDED
SEPTEMBER 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                             114
<SECURITIES>                                         0
<RECEIVABLES>                                1,065,896
<ALLOWANCES>                               (1,065,896)
<INVENTORY>                                          0
<CURRENT-ASSETS>                                   114
<PP&E>                                         100,000
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 692,228
<CURRENT-LIABILITIES>                          719,609
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         4,508
<OTHER-SE>                                   2,225,115
<TOTAL-LIABILITY-AND-EQUITY>                   692,228
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                              (89,250)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (89,250)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (89,250)
<EPS-BASIC>                                      (.02)
<EPS-DILUTED>                                    (.02)


</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Securities and Exchange Commission

          - [File No. 500-1]

It appears to the Securities and Exchange Commission that there is a lack of current and accurate information concerning the securities of PrimeGen Energy Corporation (“PrimeGen”) because of questions regarding the accuracy of publicly disseminated information concerning, among other things, the company's current financial condition, management, and business operations. PrimeGen is quoted on the Pink Sheets under the symbol “PGNE.”

The Commission is of the opinion that the public interest and the protection of investors require a suspension of trading in the securities of the above-listed company.

Therefore, it is ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading in securities of the above-listed company is suspended for the period from 9:30 a.m. EST, on March 1, 2010, through 11:59 p.m. EST, on March 12, 2010.

By the Commission.

Elizabeth M. Murphy, 

Secretary.

[FR Doc. 2010-4502 Filed 3-1-10; 11:15 am]

BILLING CODE 8011-01-P
Exhibit 32.1
                                                                  ------------
         Section 1350 Certifications of Principal Executive Officer and
                           Principal Financial Officer
            Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

         Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, the undersigned officers of 1st Independence
Financial Group, Inc. (the "Company"), hereby certify, to such officer's
knowledge, that:

         The Annual Report on Form 10-K for the year ended December 31, 2006
(the  "Report") of the Company  fully  complies  with the  requirements  of
section  13(a)  or  15(d)  of the  Securities  Exchange  Act  of  1934  and  the
information  contained in the Report fairly presents,  in all material respects,
the financial condition and results of operations of the Company.



Dated: March 15, 2007       /s/ N. William White
                                --------------------------------
                                Name:     N. William White
                                Title:    President and Chief Executive Officer
                                          (Principal Executive Officer)


                            /s/ R. Michael Wilbourn
                                --------------------------------
                                Name:     R. Michael Wilbourn
                                Title:    Executive Vice President
                                          and Chief Financial Officer
                                          (Principal Financial Officer)
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

                    By Notice dated November 23, 2009, and published in the                     **Federal Register**                     on December 2, 2009 (74 FR 63156), ISP Freetown Fine Chemicals, 238 South Main Street, Assonet, Massachusetts 02702, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in schedule II.                

The company plans to import the controlled substance to manufacture amphetamine.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of ISP Freetown Fine Chemicals to import the basic class of controlled substance is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated ISP Freetown Fine Chemicals to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substance listed.

Dated: February 25, 2009.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. 

[FR Doc. 2010-4399 Filed 3-2-10; 8:45 am]

BILLING CODE 4410-09-P
<PAGE>


                                                                    EXHIBIT 23.1

                    CONSENT OF KPMG LLP, INDEPENDENT AUDITORS

The Board of Directors
Mackie Designs, Inc.:

We consent to incorporation by reference in the registration statement (No.
33-98720) on Form S-8 of Mackie Designs, Inc. of our report dated February
22, 2000, relating to the consolidated balance sheet of Mackie Designs, Inc
as of December 31, 1999 and the related consolidated statements of income,
cash flows and shareholders' equity and comprehensive income for the year
then ended, and the related schedule for the year then ended, which report
appears in the December 31, 1999 annual report on Form 10-K of Mackie
Designs, Inc.


                                                        KPMG LLP

Seattle, Washington
March 29, 2000
§ 556.75 Bambermycins. ( a ) [Reserved]
( b ) *Tolerances.* The tolerances for bambermycins are: ( 1 ) *Cattle.* Edible tissues (excluding milk): Not required.
( 2 ) *Chickens and turkeys.* Edible tissues (excluding eggs): Not required.
( 3 ) *Swine.* Edible tissues: Not required.
( c ) *Related conditions of use.* See § 558.95 of this chapter.
EXHIBIT 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906

 OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the Annual Report on Form 10-Q (the “Form 10-Q”) for the year ended March 31, 2007 of Crimson Exploration Inc. (the “Issuer”).  The undersigned hereby certifies that the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer. 

 

| Date:

  | May 21, 2007

     |   |
|---------------|-------------------------|--------|
| /s/           | E. Joseph Grady         |   |
| Name:         | E. Joseph Grady         |   |
| Title:        | Chief Financial Officer |   |
|          |                    |   |
|          |                    |   |

 

A signed original of this written statement required by Section 906 has been provided to the Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.
§ 522.52 Alfaxalone. ( a ) *Specifications.* Each milliliter contains 10 milligrams (mg) alfaxalone.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cats and dogs* — ( 1 ) *Amount* — ( i ) *Cats* — ( A ) *Induction of general anesthesia.* Administer by intravenous injection over approximately 60 seconds or until clinical signs show the onset of anesthesia, 2.2 to 9.7 mg/kilogram (kg) for cats that did not receive a preanesthetic or 1.0 to 10.8 mg/kg for cats that received a preanesthetic.
( B ) *Maintenance of general anesthesia following induction.* Administer an intravenous bolus containing 1.1 to 1.3 mg/kg to provide an additional 7 to 8 minutes of anesthesia in preanesthetized cats; a dose containing 1.4 to 1.5 mg/kg provides an additional 3 to 5 minutes anesthesia in unpreanesthetized cats.
( ii ) *Dogs* — ( A ) *Induction of general anesthesia.* Administer by intravenous injection over approximately 60 seconds or until clinical signs show the onset of anesthesia, 1.5 to 4.5 mg/kg for dogs that did not receive a preanesthetic or 0.2 to 3.5 mg/kg for dogs that received a preanesthetic.
( B ) *Maintenance of general anesthesia following induction.* Administer an intravenous bolus containing 1.2 to 1.4 mg/kg to provide an additional 6 to 8 minutes of anesthesia in preanesthetized dogs; a dose of 1.5 to 2.2 mg/kg provides an additional 6 to 8 minutes of anesthesia in unpreanesthetized dogs.
( 2 ) *Indications for use.* For the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in dogs and cats.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian. Alfaxalone is a Class IV controlled substance.
[77 FR 64717, Oct. 23, 2012, as amended at 79 FR 64116, Oct. 28, 2014; 88 FR 84700, Dec. 6, 2023]
# C_2014175EN.01002602.xml

| 10.6.2014 | EN | Official Journal of the European Union | C 175/26 |
| --- | --- | --- | --- |

10.6.2014

EN

Official Journal of the European Union

C 175/26

---

Action brought on 21 March 2014 — European Commission v Council of the European Union

(Case C-135/14)

2014/C 175/33

Language of the case: French

Parties

Parties

Applicant: European Commission (represented by: R. Lyal, W. Mölls, and D. Bianchi, acting as Agents)

Applicant:

Defendant: Council of the European Union

Defendant:

Form of order sought

Form of order sought

| — | annul Council Regulation (EU) No 1385/2013 of 17 December 2013 amending Council Regulations (EC) No 850/98 and (EC) No 1224/2009, and Regulations (EC) No 1069/2009, (EU) No 1379/2013 and (EU) No 1380/2013 of the European Parliament and of the Council, following the amendment of the status of Mayotte with regard to the European Union. (1) |
| --- | --- |

—

annul Council Regulation (EU) No 1385/2013 of 17 December 2013 amending Council Regulations (EC) No 850/98 and (EC) No 1224/2009, and Regulations (EC) No 1069/2009, (EU) No 1379/2013 and (EU) No 1380/2013 of the European Parliament and of the Council, following the amendment of the status of Mayotte with regard to the European Union. (1)

1

| — | maintain the effects of Regulation (EU) No 1385/2013 until the entry into force of a new regulation based on appropriate legal bases. |
| --- | --- |

—

maintain the effects of Regulation (EU) No 1385/2013 until the entry into force of a new regulation based on appropriate legal bases.

| — | order the Council of the European Union to pay the costs. |
| --- | --- |

—

order the Council of the European Union to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

The Commission seeks annulment of Regulation (EU) No 1385/2013 that the Council adopted on the legal basis of Article 349 TFEU.

The Commission alleges that the Council adopted that regulation although the Commission had proposed that the act be based on sector-specific legal bases, namely Article 43(2) and Article 168(4)(b) TFEU.

It submits that, in accordance with the purpose and aim of the contested regulation, Article 349 TFEU cannot legitimately be used as a legal basis. Article 349 TFEU can be applied only when it involves derogation from the principle of application of primary law to the outermost regions, as established in Article 355(1) TFEU. However, the regulation at issue, without derogating from the Treaties, merely adapts secondary law to respond to the situation created by the change of the status of Mayotte. That interpretation is supported not only by the wording of Article 349 TFEU, but also by the system of legal bases of the Treaty, as well as by the historical origins of that article.

---

(1)  OJ 2013 L 354, p. 86.

1

---
# L_2019224EN.01001201.xml

| 28.8.2019 | EN | Official Journal of the European Union | L 224/12 |
| --- | --- | --- | --- |

28.8.2019

EN

Official Journal of the European Union

L 224/12

---

Corrigendum to Rules of Procedure of the European Economic and Social Committee March 2019

(
  Official Journal of the European Union L 110 of 25 April 2019
  )

On page 43, the publication of ‘Rules of Procedure of the European Economic and Social Committee March 2019’ is to be considered null and void.

---